OKYO Pharma Presents at Ophthalmic Conferences
News related to:OKYO Pharma Limited · 2 min read
LONDON and NEW YORK, Sept. 29, 2026 /CourierPR/ -- OKYO Pharma Limited, a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, has announced its continued commitment to the optometry and ophthalmology communities by presenting and participating at several upcoming ophthalmic conferences.
The company will be featured at the Eyecelerator conference, which is scheduled to take place on October 8, 2026, in New Orleans, Louisiana. The session will be held in the Breakout: Anterior Segment room, and Robert J. Dempsey, the Chief Executive Officer of OKYO Pharma, will be the presenter. The session will be moderated by Julie Schallhorn, MD, MS, and Kendall Donaldson, MD.
Additionally, the leadership team of OKYO Pharma will be engaging with leading optometric experts at the American Academy of Optometry conference, which will be held from September 30 to October 1 in Anaheim, California. The company's presence at this conference underscores its commitment to both optometrists and ophthalmologists, who play a crucial role in the diagnosis and care of patients with neuropathic corneal pain (NCP).
The American Academy of Ophthalmology conference, scheduled for October 9 to 12 in New Orleans, will also feature the leadership team of OKYO Pharma. This conference will provide the company with another platform to engage with leading ophthalmology experts, further solidifying its commitment to the field of ophthalmology.
OKYO Pharma's continued presence at these leading ophthalmic meetings demonstrates its dedication to both optometrists and ophthalmologists, ensuring that the company remains at the forefront of addressing unmet needs in corneal and anterior segment diseases. The company's innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases continue to be a focal point of its research and development efforts.
OKYO Pharma plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP. The company's commitment to these conferences and its ongoing clinical trials reflect its strong commitment to advancing the field of ophthalmology and improving the lives of patients suffering from corneal and anterior segment diseases.